ACADIA Pharmaceuticals v. Zydus Cadila: Consent Judgment After 979-Day Pimavanserin Patent Battle
ACADIA Pharmaceuticals filed suit in the Delaware District Court against Zydus Cadila and Cadila Healthcare Limited, asserting five patents covering pimavanserin formulations, combinations, and its tartrate salt and crystalline forms. The case resolved by Consent Judgment on April 5, 2023, after nearly three years of litigation.
Five Pimavanserin Patents, One ANDA Challenge, and a Court-Entered Resolution
On July 30, 2020, ACADIA Pharmaceuticals, Inc. filed suit in the U.S. District Court for the District of Delaware against Zydus Cadila and Cadila Healthcare Limited, asserting infringement of five patents: US7601740B2, US10449185B2, US7732615B2, US10646480B2, and US10517860B2. The patents collectively cover pimavanserin formulations, combinations with cytochrome P450 modulators, the tartrate salt and crystalline forms of the compound, and its use as a selective serotonin 2A/2C receptor inverse agonist for neurodegenerative diseases.
The recorded Basis of Termination is Consent Judgment. The docket order, however, states that the parties stipulated to dismissal of all claims and counterclaims without prejudice pursuant to Rule 41(a)(1)(A)(ii) of the Federal Rules of Civil Procedure. The specific terms underlying the resolution are not disclosed in the available public record.
The case ran for 979 days before closing on April 5, 2023 — a duration consistent with contested Hatch-Waxman ANDA litigation that often proceeds through fact discovery before parties reach resolution. What drove the timing and precise commercial terms of the agreement is not determinable from the public record.
See Complete Case & Patent Analysis →Filing to Consent Judgment in 979 days
979 days — nearly 3 years of active litigation before resolution
US7601740B2 — Pimavanserin tartrate salt and crystalline forms
Any company developing a generic, biosimilar, or next-generation CNS therapy that overlaps with pimavanserin's mechanism, formulation, or salt form should treat ACADIA's five-patent cluster as a live enforcement risk. The Consent Judgment in this case produced no invalidity finding — meaning all five patents remain presumptively valid and enforceable. Formulation teams working on serotonin 2A/2C inverse agonists or combination CNS products should prioritise FTO clearance against US7601740B2, US7732615B2, US10449185B2, US10646480B2, and US10517860B2.
Official order — verbatim text
The docket order records a Rule 41(a)(1)(A)(ii) stipulated dismissal of all claims and counterclaims without prejudice. No merits ruling on patent validity or infringement was issued. The Consent Judgment designation in the Basis of Termination reflects the court's formal entry of an agreed disposition; the specific terms underlying that agreement are not disclosed in the available record.
Consent judgment: what the agreed resolution means for both parties
What a consent judgment means in patent litigation
A consent judgment is a binding, court-entered judgment based on terms agreed between the parties. Unlike a voluntary dismissal, it constitutes an adjudication on the record and carries the full force of a court order. The court retains jurisdiction to enforce it. Here, the recorded Basis of Termination is Consent Judgment; the docket order is styled as a Rule 41(a)(1)(A)(ii) stipulated dismissal without prejudice — the specific reconciling terms are not disclosed in the available record.
Court-entered, agreed by partiesACADIA secures a court-entered resolution on five pimavanserin patents
As patent holder, ACADIA Pharmaceuticals obtained a Consent Judgment covering all five asserted patents — US7601740B2, US10449185B2, US7732615B2, US10646480B2, and US10517860B2. The judgment closes this particular challenge from Zydus. The commercial and licensing terms of the resolution are not disclosed in the available public record.
All five patents coveredZydus's ANDA challenge resolved without a merits ruling on validity
For Zydus Cadila and Cadila Healthcare Limited, the Consent Judgment ends this particular action. Because no court issued a merits ruling on patent validity or infringement, the public record does not establish whether Zydus admitted infringement or conceded the patents' validity. The specific terms of the agreement, including any market-entry or licensing provisions, are not disclosed in the available record.
No merits adjudicationPimavanserin's patent estate reinforced without trial exposure
Resolving Hatch-Waxman disputes via Consent Judgment before trial avoids the risk of an adverse validity ruling that could open the market to all generic entrants. ACADIA's five-patent portfolio around pimavanserin — covering formulations, combinations, crystalline forms, and receptor mechanism — suggests layered protection designed to extend exclusivity. Competitors and R&D teams monitoring generic entry timelines should track the specific market-entry terms, which are not disclosed in this record.
Generic entry timeline uncertainFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | ACADIA Pharmaceuticals, Inc. | Company | /Search in Eureka ↗ |
| Defendant | Zydus Cadila | Individual | /Search in Eureka ↗ |
| Co-Defendant | Cadila Healthcare Limited | Company | Search in Eureka ↗ |
| Plaintiff counsel | Bruce M. Wexler | Attorney | Counsel for ACADIA Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Chad J. Peterman | Attorney | Counsel for ACADIA Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Charles E. Davis | Attorney | Counsel for ACADIA Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | James Darlington Taylor | Attorney | Counsel for ACADIA Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jessica Marie Jones | Attorney | Counsel for ACADIA Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Scott F. Peachman | Attorney | Counsel for ACADIA Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing Arnstein & Lehr LLP | Law Firm | Representing ACADIA Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Amy M. Lange | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | Christopher J. Cassella | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | David A. Bilson | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | James T. Peterka | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | John C. Phillips | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | Michael J. Gaertner | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | Timothy F. Peterson | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant law firm | Phillips, Goldman, McLaughlin & Hall PA | Law Firm | Representing Zydus CadilaSearch in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the pimavanserin and CNS inverse agonist space
Forward-looking patent and R&D intelligence signals derived from ACADIA's five-patent pimavanserin assertion and Zydus's competitive position in CNS generics.
ACADIA's pimavanserin patent cluster: coverage and expiry horizon
ACADIA has built a multi-layered patent estate around pimavanserin spanning compound salt forms, crystalline structures, formulations, CYP450 combinations, and receptor mechanism. Tracking the filing and priority dates of each layer — and any post-grant proceedings — reveals the window within which generic challengers can realistically seek market entry. The estate suggests active continuation filing activity worth monitoring.
Lifecycle IP strategySerotonin 2A/2C inverse agonist filing trends in neurodegeneration
Pimavanserin's mechanism — selective 5-HT2A/2C inverse agonism — is attracting growing R&D interest beyond Parkinson's disease psychosis, including Alzheimer's-related psychosis and other neurodegenerative indications. Patent filings in this receptor class have accelerated, with competitors exploring structurally distinct inverse agonists designed to work around ACADIA's core claims. Mapping this landscape can identify freedom-to-operate paths and white space.
5-HT2A inverse agonist landscapeZydus Cadila's CNS generics and patent challenge strategy
Zydus Cadila (Cadila Healthcare) has an active ANDA and generic pharmaceutical programme across multiple CNS drug classes. Understanding their paragraph IV certification history, post-grant challenge filings (IPR/PGR), and in-house CNS patent activity can signal which branded CNS products they may target next and how they structure their invalidity arguments against multi-patent estates like ACADIA's.
Generic challenger IP profileCYP450 combination and co-administration claims: adjacent R&D space
US10449185B2's claims around pimavanserin combined with CYP450 modulators represent a specific combination-therapy claim layer. Adjacent white space exists for novel CNS combinations that avoid pimavanserin's specific compound while targeting similar metabolic interactions or receptor co-modulation. R&D teams exploring polypharmacology approaches in CNS may find opportunity in structurally distinct inverse agonist scaffolds with complementary CYP450 profiles.
Combination therapy white spaceSimilar Hatch-Waxman CNS pharmaceutical patent cases in Delaware
Explore comparable ANDA-driven patent infringement actions in the Delaware District Court involving CNS drug formulations, crystalline form patents, and serotonin receptor therapeutics.
What this case signals for the pimavanserin IP landscape
Five patents, one consent judgment, no merits ruling — the pimavanserin patent estate remains untested in court.
Layered patent portfolios in CNS drugs raise the cost of generic entry
ACADIA's assertion of five patents — spanning formulation, combination therapy, crystalline form, and receptor mechanism — is consistent with a lifecycle-management strategy that forces generic challengers to contest multiple patent claims simultaneously. Generic entrants and ANDA filers in the CNS space should model the full patent cluster, not just the primary compound patent.
Consent Judgment without a merits ruling leaves validity questions open
Because no court adjudicated the validity or infringement of ACADIA's five pimavanserin patents, those questions remain unresolved in public law. Any subsequent ANDA challenger will need to conduct independent validity analysis — particularly for the crystalline form and combination-therapy claims, which are often the most commercially significant and the most litigation-tested in branded CNS drug portfolios.
ACADIA v Zydus — key questions answered
ACADIA asserted five patents: US7601740B2 (pimavanserin tartrate salt and crystalline forms), US10449185B2 (combinations with CYP450 modulators), US7732615B2 (N-(4-fluorobenzyl) carbamide compound), US10646480B2 (formulations), and US10517860B2 (selective serotonin 2A/2C receptor inverse agonists for neurodegenerative diseases). All five patents relate to different protective layers around pimavanserin, the active ingredient in ACADIA's Nuplazid.
The recorded Basis of Termination is Consent Judgment. The docket order, however, is styled as a Rule 41(a)(1)(A)(ii) stipulated dismissal of all claims and counterclaims without prejudice. The specific terms underlying the resolution are not disclosed in the available public record. These two characterisations appear in the record as stated; reconciliation is left to the reader.
No. The case resolved by Consent Judgment without any court adjudication of patent validity or infringement. All five asserted pimavanserin patents therefore remain presumptively valid and enforceable. Future ANDA challengers cannot rely on any invalidity finding from this proceeding.
The case was filed on July 30, 2020 and closed on April 5, 2023 — a duration of 979 days, approximately 32 months. This is consistent with Hatch-Waxman ANDA litigation timelines in the Delaware District Court, where cases frequently proceed through fact discovery and sometimes claim construction before reaching resolution.
US7601740B2 and US7732615B2 protect the tartrate salt and crystalline forms of pimavanserin — the physical state in which the drug is commercially manufactured. These claim layers often carry significant exclusivity tails beyond the base compound patent. Because no invalidity ruling was issued in this case, these patents remain active barriers. Any generic or ANDA filer must independently assess their validity and conduct FTO analysis before market entry.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.